Patents Assigned to University of Montpellier I
-
Patent number: 8710089Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).Type: GrantFiled: September 13, 2010Date of Patent: April 29, 2014Assignees: Zentaris GmbH, Le Centre National de la Recherche Scientifique, University of Montpellier I, University of Montpellier IIInventors: Daniel Perrissoud, Jean Martinez, Aline Moulin, Jean-Alain Fehrentz, Damien Boeglin, Luc Demange
-
Patent number: 8546435Abstract: The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors.Type: GrantFiled: September 16, 2011Date of Patent: October 1, 2013Assignees: AEterna Zentaris GmbH, Centre National de la Recherche Scientifique, University of Montpellier I, University of Montpellier IIInventors: Babette Aicher, Gilbert Mueller, Klaus Paulini, Lars Blumenstein, Peter Schmidt, Matthias Gerlach, Michael Teifel, Jean Martinez, Jean-Alain Fehrentz, Anne-Laure Blayo
-
Publication number: 20120083494Abstract: The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors.Type: ApplicationFiled: September 16, 2011Publication date: April 5, 2012Applicants: AETERNA ZENTARIS GmbH, University of Montpellier Il, University of Montpellier I, Centre National De La Recherche Scient.Inventors: Babette Aicher, Gilbert Mueller, Klaus Paulini, Lars Blumenstein, Peter Schmidt, Matthias Gerlach, Michael Teifel, Jean Martinez, Jean-Alain Fehrentz, Anne-Laure Blayo
-
Publication number: 20100331343Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).Type: ApplicationFiled: September 13, 2010Publication date: December 30, 2010Applicants: ZENTARIS GmbH, Le Centre National De La Recherche Scientifique, University of Montpellier I, University of Montpellier IIInventors: Daniel PERRISSOUD, Jean Martinez, Aline Moulin, Jean-Alain Fehrentz, Damien Boeglin, Luc Demange
-
Patent number: 7829724Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).Type: GrantFiled: August 11, 2006Date of Patent: November 9, 2010Assignees: Zentaris GmbH, Le Centre National de la Recherche Scientifique, University of Montpellier I, University of Montpellier IIInventors: Daniel Perrissoud, Jean Martinez, Aline Moulin, Jean-Alain Fehrentz, Damien Boeglin, Luc Demange
-
Publication number: 20090239877Abstract: The invention provides 1,2,4-triazole compounds, compositions containing those compounds, methods of treating diseases and/or disorders with those compounds and processes of manufacturing 1,2,4-triazole compounds.Type: ApplicationFiled: March 17, 2009Publication date: September 24, 2009Applicants: AETERNA ZENTARIS GmbH, CENTRE NAT DE LA RECHERCHE SCIENTIFIQUE, University of Montpellier I, University of Montpellier IIInventors: Jean-Alain Fehrentz, Mathieu Bibian, Aline Moulin, Jean Martinez
-
Publication number: 20070037857Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).Type: ApplicationFiled: August 11, 2006Publication date: February 15, 2007Applicants: ZENTARIS GmbH, Le Centre National De La Recherche Scientifique, University of Montpellier I, University of Montpellier IIInventors: Daniel Perrissoud, Jean Martinez, Aline Moulin, Jean-Alain Fehrentz, Damien Boeglin, Luc Demange
-
Patent number: 5957975Abstract: The present invention provides a biodegradable polymeric stent having a programmed pattern of in vivo degradation. When deployed, the stent comprises a substantially cylindrical element having two open ends and a plurality of regions circumferentially spaced around the cylindrical element and extending from one open end to the other open end of the cylindrical element. Each of the regions is configured to have a desired in vivo lifetime. One region is designed to have a shorter in vivo lifetime than the other region or regions so that when the stent is deployed within the lumen of a vessel of a patient, the cylindrical element breaks apart from one open end of the cylindrical element to the other open end of the cylindrical element within a predetermined period of time after the stent is deployed in the patient. In one preferred embodiment the stent is a formed from a biodegradable polymeric band. The band includes a head having a slot and a tongue having a catch mechanism.Type: GrantFiled: December 15, 1997Date of Patent: September 28, 1999Assignees: The Cleveland Clinic Foundation, The University Paris V, Faculte Necker, The Centre National de la Recherche Scientifique, The University of Montpellier IInventors: Antoine Lafont, Michel R. Vert, Fredrick Cornhill, Suming Li, Henri L. Garreau